Mission Bio

The companies will co-create bioinformatics tools for researchers in China.

Through an early-access program, the company is hoping to show that its platform can identify measurable residual disease in AML more accurately than current methods.

Although the technology has largely been used in research, the firm is optimistic it can overcome data and workflow challenges and bring it to the clinic.